TEVA TEVA Pharmaceutical Industriesdata gap · 80% coverage
Health Care · Pharmaceutical Preparations · close $41.50 (2026-10-16) · latest quarter in EDGAR: 2026-06-30
TEVA Pharmaceutical Industries (TEVA) has a ThetaGrade House Rating of 32/100 (grade F), ranking #46 of 150 in Health Care. Its strongest pillars are profitability (63) and cash flow (40); its weakest is balance sheet (8). Data gap: 3 factors without usable data, so 80% of the method weight is covered. TTM revenue growth is 4.1% and operating margin 9.3%.
Data as of .
Data gap
No usable data for: Consensus score (1–5), 90-day net rating shift, EPS growth YoY (TTM). Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 80% of the full method weight is backed by data.
Analyst sentiment
weight 7.5% · no data · —| Consensus score (1–5) (0.0%)data gap | derived | — |
| 90-day net rating shift (0.0%)data gap | derived | — |
Growth
weight 30.83% (→33.3%) · 22| Revenue growth YoY (TTM) (22.2%) | 4.1% | 19 |
| EPS growth YoY (TTM) (0.0%)data gap | — | — |
| Revenue acceleration (11.1%) | -3.2% | 28 |
Profitability
weight 18.5% (→20.0%) · 63| Operating margin (10.7%) | 9.3% | 41 |
| 4Q gross-margin change (9.3%) | 2.9% | 89 |
Balance sheet
weight 18.5% (→20.0%) · 8| Net debt / EBITDA (10.7%) | 11.39× | 2 |
| Current ratio (5.3%) | 0.88 | 5 |
| Interest coverage (4.0%) | 1.75× | 28 |
Cash flow
weight 12.33% (→13.3%) · 40| FCF margin (6.7%) | 6.7% | 35 |
| FCF yield (6.7%) | 2.4% | 45 |
Valuation
weight 12.33% (→13.3%) · 36| P/E (inverted) (6.7%) | 68.03× | 16 |
| EV/Sales (inverted) (6.7%) | 4.51× | 56 |
Technicals (EOD)
| RSI(14) | 65.4 |
| EMA 9 / 21 | 40.68 / 39.87 |
| 200-day SMA | 34.15 |
| Volume vs 20d avg | 0.93× |
| 20-day return | 5.9% |
Exit-rule monitor
- EXITRating break: House Rating below 60
- EXITBalance-sheet stress: net debt/EBITDA above 4×
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Gross profit: GrossProfit · Operating income: OperatingIncomeLoss · Interest expense: InterestExpense · D&A: DepreciationAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).
Get rating changes like TEVA's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is TEVA's House Rating?
- TEVA scores 32 out of 100 (grade F) as of 2026-10-16, ranking #46 of 150 Health Care stocks we cover.
- What do analysts say about TEVA?
- We do not have enough analyst-sentiment data to score this stock.
- When does TEVA report earnings next?
- We do not have a reliable estimate for TEVA's next earnings date (irregular SEC filing history); a rough window is 2026-07-29 to 2027-02-10. Check the company's investor-relations page.
- Is TEVA a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology